Regeneron Pharmaceuticals Forecast, price target & analysts
Regeneron Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Regeneron Pharmaceuticals Classifications & Recommendation:
Regeneron Pharmaceuticals Price Target
| Target Price | $762.52 |
| Price | $525.00 |
| Potential | 45.24% |
| Number of Estimates | 28 |
| 28 Analysts have issued a price target Regeneron Pharmaceuticals 2026 . The average Regeneron Pharmaceuticals target price is $762.52. This is 45.24% higher than the current stock price. The highest price target is $1,063.65 102.60% , the lowest is $509.04 3.04% . | |
| A rating was issued by 34 analysts: 25 Analysts recommend Regeneron Pharmaceuticals to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2026 of 45.24% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
29 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals sales estimate is $13.7b . This is 2.98% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $14.9b 5.88% , the lowest is $12.4b 11.85% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $14.2b | 8.27% |
|---|---|---|
| 2025 | $13.7b | 3.77% |
| 2026 | $14.6b | 6.78% |
| 2027 | $16.2b | 10.73% |
| 2028 | $17.0b | 5.15% |
| 2029 | $17.9b | 5.58% |
| 2030 | $18.7b | 4.38% |
| 2031 | $19.3b | 3.28% |
| 2032 | $18.8b | 2.77% |
14 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2025. The average Regeneron Pharmaceuticals EBITDA estimate is $4.4b . This is 2.59% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $5.5b 21.45% , the lowest is $3.4b 25.21% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $4.7b | 1.17% |
|---|---|---|
| 2025 | $4.4b | 5.53% |
| 2026 | $5.2b | 17.74% |
| 2027 | $6.4b | 21.53% |
| 2028 | $6.4b | 0.82% |
| 2029 | $7.1b | 11.19% |
| 2030 | $7.7b | 7.71% |
| 2031 | $8.0b | 4.42% |
| 2032 | $7.1b | 11.00% |
EBITDA Margin
| 2024 | 33.10% | 8.72% |
|---|---|---|
| 2025 | 32.50% | 1.81% |
| 2026 | 35.83% | 10.25% |
| 2027 | 39.33% | 9.77% |
| 2028 | 37.71% | 4.12% |
| 2029 | 39.72% | 5.33% |
| 2030 | 40.98% | 3.17% |
| 2031 | 41.44% | 1.12% |
| 2032 | 37.93% | 8.47% |
30 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Regeneron Pharmaceuticals net profit estimate is $3.9b . This is 12.74% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.8b 6.94% , the lowest is $3.2b 28.38% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $4.4b | 11.61% |
|---|---|---|
| 2025 | $3.9b | 11.03% |
| 2026 | $4.4b | 11.63% |
| 2027 | $5.4b | 22.14% |
| 2028 | $5.9b | 9.80% |
| 2029 | $6.5b | 10.14% |
| 2030 | $7.0b | 7.98% |
| 2031 | $7.5b | 7.19% |
| 2032 | $7.3b | 3.13% |
Net Margin
| 2024 | 31.07% | 3.08% |
|---|---|---|
| 2025 | 28.73% | 7.53% |
| 2026 | 30.03% | 4.52% |
| 2027 | 33.13% | 10.32% |
| 2028 | 34.60% | 4.44% |
| 2029 | 36.09% | 4.31% |
| 2030 | 37.34% | 3.46% |
| 2031 | 38.75% | 3.78% |
| 2032 | 38.61% | 0.36% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
30 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals EPS is $36.28 . This is 10.33% lower than earnings per share in the financial year 2024. The highest EPS forecast is $44.47 9.91% , the lowest is $29.78 26.40% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $38.34 | 10.27% |
|---|---|---|
| 2025 | $36.28 | 5.37% |
| 2026 | $40.51 | 11.66% |
| 2027 | $49.47 | 22.12% |
| 2028 | $54.32 | 9.80% |
| 2029 | $59.83 | 10.14% |
| 2030 | $64.61 | 7.99% |
| 2031 | $69.25 | 7.18% |
| 2032 | $67.09 | 3.12% |
P/E ratio
| Current | 12.88 | 59.03% |
|---|---|---|
| 2025 | 14.36 | 11.52% |
| 2026 | 12.86 | 10.45% |
| 2027 | 10.53 | 18.12% |
| 2028 | 9.59 | 8.93% |
| 2029 | 8.71 | 9.18% |
| 2030 | 8.06 | 7.46% |
| 2031 | 7.52 | 6.70% |
| 2032 | 7.77 | 3.32% |
Based on analysts' sales estimates for 2025, the Regeneron Pharmaceuticals stock is valued at an EV/Sales of 3.70 and an P/S ratio of 4.12 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.59 | 56.54% |
|---|---|---|
| 2025 | 3.70 | 3.15% |
| 2026 | 3.47 | 6.35% |
| 2027 | 3.13 | 9.69% |
| 2028 | 2.98 | 4.90% |
| 2029 | 2.82 | 5.28% |
| 2030 | 2.70 | 4.19% |
| 2031 | 2.62 | 3.17% |
| 2032 | 2.69 | 2.85% |
P/S ratio
| Current | 3.99 | 54.92% |
|---|---|---|
| 2025 | 4.12 | 3.07% |
| 2026 | 3.85 | 6.35% |
| 2027 | 3.48 | 9.69% |
| 2028 | 3.31 | 4.90% |
| 2029 | 3.14 | 5.29% |
| 2030 | 3.00 | 4.19% |
| 2031 | 2.91 | 3.18% |
| 2032 | 2.99 | 2.85% |
Regeneron Pharmaceuticals...
Current Regeneron Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Jun 09 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Jun 05 2025 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Jun 02 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Jun 02 2025 |
| BMO Capital |
Outperform
➜
Outperform
|
Unchanged | Jun 02 2025 |
| Wells Fargo |
Overweight
➜
Equal-Weight
|
Downgrade | May 30 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | May 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Jun 09 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Jun 05 2025 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Jun 02 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Jun 02 2025 |
|
Unchanged
BMO Capital:
Outperform
➜
Outperform
|
Jun 02 2025 |
|
Downgrade
Wells Fargo:
Overweight
➜
Equal-Weight
|
May 30 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
May 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
